Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Background: Cohort studies have reported that midlife high total serum cholesterol (TC) is associated with increased risk of Alzheimer’s disease (AD) in late-life but findings have been based on few studies and previous reviews have been limited by a lack of compatible data. Objective: We synthesized all high quality data from cohort studies reporting on the association between total serum cholesterol measured and late-life cognitive outcomes including Alzheimer’s disease (AD), vascular dementia (VaD), any dementia, mild cognitive impairment (MCI), and cognitive decline. Methods: The literature was searched up to October 2016 using a registered protocol. Thirty-four articles meeting study criteria were identified. Seventeen studies published from 1996 to 2014, including 23,338 participants were included in meta-analyses. Results: Relative risk of developing AD for adults with high TC in midlife was 2.14 (95% CI 1.33–3.44) compared with normal cholesterol. Individual studies that could not be pooled also reported high TC in midlife increased the risk of MCI and cognitive decline in late-life. High TC in late-life was not associated with MCI, AD, VaD, any dementia, or cognitive decline. Late-life measured HDL cholesterol and triglycerides were not associated with increased risk of VaD, and HDL was not associated with risk of MCI, AD, or any dementia. There were insufficient data to examine other cholesterol sub-fractions, sex differences, or APOE interactions. Conclusions: Significant gaps in the literature regarding TC and late-life dementia remain. Evidence suggests that high midlife TC increases risk of late-life AD, and may correlate with the onset of AD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meta-analytic evidence found inconsistent evidence from HICs that high LDL-C in midlife, but not in later life, might be a risk factor for cognitive decline, all cause dementia and AD.”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [151]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, midlife obesity, 105,111,112 hypertension, 85,[105][106][107] prehypertension (systolic blood pressure from 120 to 139 mm Hg or diastolic pressure from 80 to 89 mm Hg) 85 and high cholesterol 113 are associated with an increased risk of dementia in later life.”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [113]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Systematic review evidence has shown there is no consistent evidence linking high cholesterol in midlife or late-life to risk of vascular dementia, and no consistent evidence linking high cholesterol in late-life to risk of AD (5).”
From Oversimplification of Dementia Risk Reduction Messaging Is a Threat to Knowledge Translation in Dementia Prevention Research (2018) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Systematic review evidence has shown there is no consistent evidence linking high cholesterol in midlife or late-life to risk of vascular dementia, and no consistent evidence linking high cholesterol in late-life to risk of AD (5).”
From Oversimplification of Dementia Risk Reduction Messaging Is a Threat to Knowledge Translation in Dementia Prevention Research (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“If there was evidence of heterogeneity and four or more studies were available, random effects meta-analysis was used [18, 19].”
MethodQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Heterogeneity among studies was examined using standard I2 which estimates the proportion of variance due to heterogeneity [16].”
MethodPRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223 · cited 1×
“MATERIALS AND METHODS Registration of protocol and reporting The review was registered with the International Prospective Register of Systematic Reviews (PROSPERO CRD42015026727) [6] and reported in accordance with the PRISMA checklist [7].”
MethodStang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396 · cited 2×
“Additional quality ratings were conducted for all studies meeting criteria using a checklist adapted from previous reviews, and the Newcastle Ottawa scale [8, 9].”
BackgroundMethodBorenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · cited 1×
“For clinical diagnosis of MCI, we accepted Petersen [13], Winblad [14], or other widely accepted clinical research criteria.”
MethodCurrent concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781 · cited 1×
“For clinical diagnosis of MCI, we accepted Petersen [13], Winblad [14], or other widely accepted clinical research criteria.”
MethodHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 2×
“However, studies publishing on midlife lacked clear information on the age range of the sample at baseline and the distribution of the sample within midlife and late-life [12, 21].”
Background
Research works printed but not linked: 4
- 2005, Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]
- Slooter AJC, 2000, Neurology, 54, 2357
- Liao PJ, 2015, Int J Clin Exp Med, 8, 19200
- McGuinness B, 2016, Cochrane Database Syst Rev, 1, CD003160
Cited by
Items 201–300 of 359
Kim, M., Kwasny, M., Bailey, S. C., Benavente, J. Y., Zheng, P., Bonham, M., Luu, H. Q., Cecil, P., Agyare, P., O’Conor, R. M., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-071899 · Cited by 12
Chen, Y., Yang, K., Huang, Y., Wang, X., Zhao, Y., Ping, P., Guan, S., & Fu, S. (2023) · MedComm · doi:10.1002/mco2.362 · Cited by 10
Cao, S., Teng, L., Gao, M., Hu, S., Xiao, S., Chen, C., He, Y., Cheng, S., & Xie, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27943 · Cited by 9
Wei, S., Dang, L., Gao, F., Wang, J., Wang, J., & Qu, Q. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220240 · Cited by 9
“Based on evidence that elevated cholesterol levels are significantly associated with an increased risk of developing AD [15, 16], statins are proposed as crucial tools for the interventional treatment of AD.”
Huan, S., Liu, M., Liu, Z., Gao, J., & Yin, G. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230422 · Cited by 8
“A high-qualitymeta-analysisincorporating34relevant studies has also demonstrated a significant increase in the risk of developing AD in individuals with elevated serum TC levels [47].”
Dang, L., Wei, S., Zhao, Y. C., Zhou, R., Shang, S., Gao, F., Wang, J., Wang, J., & Qu, Q. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02398-1 · Cited by 8
Huang, X., Guo, Y., Li, P., Ma, X., Dong, S.-Y., Hu, H., Li, Y., & Yuan, L. (2020) · The journal of nutrition health & aging · doi:10.1007/s12603-020-1328-1 · Cited by 8
Pal, L., Morgan, K. N., Santoro, N. F., Manson, J. E., Taylor, H. S., Miller, V. M., Brinton, E. A., Løbo, R. A., Neal-Perry, G. S., Cedars, M. I., et al. (2022) · Maturitas · doi:10.1016/j.maturitas.2022.04.004 · Cited by 11
Lipidomics and cognitive dysfunction – A Narrative review
Chakraborty, A., Praharaj, S. K., Prabhu, R. V. K., & Prabhu, M. M. (2020) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2020-0134 · Cited by 9
Zhang, H., Huang, R., Tian, S., An, K., Zhu, W., Shi, J., Cao, W., & Wang, S. (2020) · BioMed Research International · doi:10.1155/2020/4935831 · Cited by 9
“While the important role of cholesterol in the process of cognition decline is well recognized [33, 34], the role of cholesterol and the genetic factors regulating the metabolism of cholesterol in cognitive impairment with T2DM remains undiscovered.”
BackgroundHan, S., Byun, M. S., Yi, D., Jung, J., Kong, N., Chang, Y. Y., Keum, M., Jung, G. J., Lee, J.-Y., Lee, Y. S., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.131 · Cited by 8
Adverse Lipid Profiles Are Associated with Lower Dementia Risk in Older People
Schroevers, J. L., Richard, E., Hoevenaar‐Blom, M. P., van den Born, B. H., van Gool, W. A., van Charante, E. P. M., & van Dalen, J. W. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.105132 · Cited by 10
Relationship between residual cholesterol and cognitive performance: a study based on NHANES
Liu, K., Fu, H., Chen, Y., Li, B., Huang, H., & Liao, X. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1458970 · Cited by 7
Niu, T., Wang, S., Zhang, H., Zhu, W., Liu, K., Zhou, X., Sun, R., Niu, D., & Yuan, Y. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01534-w · Cited by 7
Yu, C., Wang, W., Shi, L., Ma, R., Zhang, Y., Zhang, C., Wang, X., Wang, T., Zheng, Y., & Tian, J. (2025) · npj Aging · doi:10.1038/s41514-025-00303-3 · Cited by 8
“For instance, signi fi cant elevations are often detected in the prodromal or MCI stages, as observed in our cohort and supported by prior work 33 , whereas differences may attenuate in advanceddementiacohorts 34 .”
Jeong, S. H., Chung, S. J., Yoo, H. S., Jung, J. H., Baik, J. S., Sohn, Y. H., & Lee, P. H. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01326-2 · Cited by 7
“When examining the association between cholesterol levels and Alzheimer’s disease or vascular dementia, previous studies have shown inconsistent results, and this association seems to vary with age at measurement (mid-life [ 65 years] or later life [ ≥ 65 years]) and follow-up duration [31, 32].”
ResultLiu, P., Liu, J., Zhang, Y., Xing, X., Zhou, L., Qu, J., & Yan, X. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02032-0 · Cited by 10
“Serum lipids are commonly used as indicators in health screenings, and accumulating evidence has revealed their associations with the potential risk of dementia, particularly AD [20–22].”
BackgroundMisfolded proteins as a therapeutic target in Alzheimer's disease
Liyanage, S. I., & Weaver, D. F. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.003 · Cited by 10
Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease
Hone, E., Lim, F., & Martins, I. J. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch7 · Cited by 9
Loika, Y., Loiko, E., Culminskaya, I. V., & Kulminski, A. M. (2023) · Genes · doi:10.3390/genes14101834 · Cited by 8
“For instance, increased levels of LDL-C and TC are considered risk factors for AD [6,7], while increased levels of HDL-C were highlighted as protective [8].”
BackgroundShen, H., Xiong, Y., Liang, Y., Liu, Z., Guo, L., Qin, Y., He, J., & Lin, F. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s506570 · Cited by 6
Bioactive compounds and dietary patterns in Alzheimer's disease
Christimann, G., dos Santos, G. R., & Sattler, J. A. G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251319048 · Cited by 8
“108 Results from a study showed that a higher intake of vitamin E and α -tocopherol equivalents was associated with a reduced incidence of AD and a slower rate of cognitive decline.”
Boccardi, V., Mancinetti, F., Guazzarini, A. G., Murasecco, I., Melis, F., Bastiani, P., Scamosci, M., Cecchetti, R., & Mecocci, P. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-02976-y · Cited by 9
“In contrast, others found no significant association between serum lipid levels and cognitive function in older adults [23, 24].”
Axelsson, E., Wallin, A., & Svensson, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191077 · Cited by 7
“AlsoinVaD, themidlifeassociationsbetweenvascularfactorsand VaDriskmightbeweakenedduringtheyearsclosest tothemanifestdisease[14,21,22,24].”
Liu, L., Huang, X. B., Feng, L., & Wu, Y. (2020) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317520962660 · Cited by 7
“Low triglycerides values were generally beneficial to maintaining cognitive abilities, but findings on the relationship between cholesterol levels and cognitive impairment are inconsistent.(29) High cholesterol levels were reported to be Table 3.”
BackgroundKuller, L. H. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.12.011 · Cited by 7
Ai, Y., Zhou, C., Wang, M., Yang, C., Zhou, S., Dong, X., Ye, N., Li, Y., Wang, L., Ren, H., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1332767 · Cited by 5
“Hyperlipidemia was found to be a potential risk factor for cognitive impairment (Anstey et al., 2017).”
BackgroundPlasma Lipids, Apolipoproteins, and Subsequent Cognitive Decline in Men with Coronary Heart Disease
Lutski, M., Weinstein, G., Goldbourt, U., & Tanné, D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180849 · Cited by 6
“…± 0.10 0.043 –0.210 ± 0.10 0.041 –0.162 ± 0.12 0.162 Executive function –0.021 ± 0.08 0.788 0.040 ± 0.49 0.936 –0.001 ± 0.08 0.992 –0.040 ± 0.09 0.653 –0.054 ± 0.10 0.580 Visual spatial –0.093 ± 0.11 0.389 –0.03 ± 0.11 0.805 0.010 ± 0.12 0.939 –0.030 ± 0.12 0.980 –0.061 ± 0. tia outcomes [30].”
InfluentialDietary Components and Nutritional Strategies for Dementia Prevention in the Elderly
Cao, X., Xu, W., Wang, Z.-T., Tan, L., & Yu, J.-T. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230609155932 · Cited by 5
af Geijerstam, P., Chalmers, J. P., Pikkemaat, M., Peters, R. K., Marre, M., Mancia, G., Woodward, M., & Harris, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02894-3 · Cited by 6
“HDL and LDL were not associated with dementia or cognitive decline (CD), but few studies reported relevant data [7, 8].”
Self-citationThe longitudinal association between dyslipidemia and cognitive trajectory
Pink, A., Krell‐Roesch, J., Syrjanen, J. A., Vassilaki, M. E., Fields, J. A., Iglseder, B., Aigner, E. S., Kremers, W. K., Jack, C. R., Racette, S. B., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251385255 · Cited by 6
“34 We observed that individuals with dyslipidemia and higher age declined statistically signi fi cantly faster over time in z-scores of attention.”
Wen, J., Hao, X., Jia, Y., Wang, B., Pang, J., & Liang, F. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231195 · Cited by 7
Liu, W., Zhou, C. L., Wang, Y., Yu, H., Zhang, X., Wang, T., Wang, L., Hao, L., Qin, Z., & Xiao, R. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab296 · Cited by 5
“Several animal and human studies reported that concentrations of oxysterols are correlated with cognitive decline (26).”
BackgroundVintimilla, R., Nevin, T., Hall, J. R., Johnson, L. A., & O’Bryant, S. E. (2022) · Gerontology and Geriatric Medicine · doi:10.1177/23337214221142958 · Cited by 4
“, 2018) and increased risk of dementia (Anstey et al., 2017).”
BackgroundChou, P., Chen, S. C.-J., Hsu, C., Liou, L., Juan, C.-H., & Lai, C. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020192 · Cited by 6
“However, previous studies have reported conflicting results on the relationship between blood total cholesterol (TC) levels and cognitive impairment: the effect of cholesterol on cognition is strongly dependent on age [14] and possibly modified by vascular risk factors [15] and cholesterol subfractions [16].”
ResultLi, W., Zhou, Y., Luo, Z., Tang, R., Sun, Y., He, Q., Xia, B., Lu, K., Hou, Q., & Yuan, J. (2023) · The FASEB Journal · doi:10.1096/fj.202201584rr · Cited by 8
Cyclodextrins as promising therapeutics against cholesterol overload
Zákány, F., Kovács, T., Szente, L., & Varga, Z. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00028-6 · Cited by 7
Loika, Y., Loiko, E., Feng, F., Stallard, E., Yashin, A. I., Arbeev, K. G., Kuipers, A. L., Feitosa, M. F., Province, M. A., & Kulminski, A. M. (2023) · Aging · doi:10.18632/aging.204665 · Cited by 5
Ide, K., Mizushima, S., Saito, K., Suzuki, H., Chiba, Y., Abe, K., Yoshimi, A., Hishimoto, A., Yamanaka, T., Sakurai, T., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251344222 · Cited by 5
Zuliani, G., & Cervellati, C. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03217-y · Cited by 4
Sun, Q.-Q., Bao, M., Gao, R., Wang, S.-K., Zhang, Y., Wang, L.-B., Zhang, Y., & Li, X. (2026) · Clinical Science · doi:10.1042/cs20258150 · Cited by 4
Gentreau, M., Miguet, M., Affatato, O., Rukh, G., & Schiöth, H. B. (2024) · Brain Communications · doi:10.1093/braincomms/fcae417 · Cited by 5
“42 This emphasizes the importance of early prevention of cardiovascular risk factors to promote long-term brain health.”
Fluorescent method for acetylcholinesterase activity detection and its inhibitors screening
Xiao, M., Tang, Y., Liu, A., Zhang, X., Wang, C., & Wei, W. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.114147 · Cited by 4
Racsa, P. N., Booth, T. A., Chung, L. N., Dixon, S. W., & Poonawalla, I. B. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_935_23 · Cited by 6
“[17] Optimally treating diabetes, hypertension, and hyperlipidemia may decrease the risk of cognitive decline and dementia, [18‑20] though results from individual randomized, placebo‑controlled trials are conflicting.”
BackgroundExperimental Analysis of Interacting HT22 Plasma Membrane Cholesterol and β-Amyloid
Livadiotis, G., Assas, L., Dayeh, M. A., Elaydi, S., Phea, C., Roberts, J. L., Samman, Y., & Tchen, R. (2017) · Advances in Alzheimer s Disease · doi:10.4236/aad.2017.64006 · Cited by 4
Thompson, F., Russell, S., Harriss, L. R., Esterman, A., Taylor, S., Quigley, R., Strivens, E., & McDermott, R. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.782373 · Cited by 4
Jibril, A. T., Arero, A. G., Kankam, S. B., & Fuseini, M. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.12.011 · Cited by 8
Statins - From Lipid-Lowering Benefits to Pleiotropic Effects
Liu, D. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001540 · Cited by 5
Genetic, clinical, and biochemical aspects of patients with Alzheimer disease
El-Tallawy, H. N., Saadeldin, H. M., Ezz-Eldin, A. M., Tohamy, A. M., Eltellawy, S., Bathalath, A. M., & Shehab, M. M. (2022) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-022-00455-z · Cited by 4
Seok, J., Kim, K., Hwang, S., Lee, K. H., & Kim, J. U. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1592341 · Cited by 3
Nyulas, K.-I., Germán-Salló, M., Fazakas, Z., Preg, Z., Pál, T., Pál, S., Tripon, R. G., Cseh, M. J., Simon-Szabó, Z., Arbănași, E. M., et al. (2023) · Life · doi:10.3390/life13020311 · Cited by 5
“Increasing the quantity of fibers in the diet of the hypertensive patients could be beneficial for cholesterol homeostasis [55].”
BackgroundBertolotti, M., Lancellotti, G., & Mussi, C. (2024) · Journal of Gerontology and Geriatrics · doi:10.36150/2499-6564-n637 · Cited by 11
Lee, D. Y., Jeong, J., & Choi, W.-I. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300784 · Cited by 3
de Coca, T. L., Moreno, L., Pardo, J., Pérez‐Tur, J., Ramos, H., & Villagrasa, V. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1395877 · Cited by 4
Exploring the connection between dementia and cardiovascular risk with a focus on ADAM10
Targas, A. B. A., Victoriano, P. H. M., Garcia, M. B. B., Alexandre-Silva, V., & Cominetti, M. R. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167825 · Cited by 3
Putra, S. E., Hia, B., Hafizhan, M., Febrianty, A. F., & Tyas, F. N. I. (2021) · Callosum Neurology · doi:10.29342/cnj.v4i1.135 · Cited by 3
“the aging process and hypercholesterolemic conditions could cause microglia activation and beta Aβ plaque deposits.(26) In contrast, study of Ma et al.”
ResultMeirelles, O., Arnette, A., Gudnason, V. G., & Launer, L. J. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-023-01087-0 · Cited by 4
“These risk factors have an established body of research into their association with CD and have been robustly measured in all cohorts using standardized methods [2, 3, 14–17].”
Karazurna, N., Porter, C. M., Aytur, S., Scott, T. M., Mattei, J., Feldeisen, S. E., Gonzalez, H. L., Mossavar‐Rahmani, Y., Sotres‐Alvarez, D., Gallo, L. C., et al. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521003275 · Cited by 3
“Evidence from randomised controlled trial supports that γ -linolenic acid and LA intake improves total cholesterol (77) , which is adversely related to dementia (78) .”
PAULA, T. C. M. D. (2022) · International Journal of Development Research · doi:10.37118/ijdr.25051.08.2022 · Cited by 3
Reducing excess dietary saturated fat intake to improve cognition in vascular dementia
Blake, S. M., Harding, T., Blake, C. P., & Borman, P. L. (2022) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2022.12.2.0220 · Cited by 4
Pradotto, L., Cattaldo, S., Priano, L., Cremascoli, R., Prina, E., Milesi, A., Mai, S., Piterà, P., Tripodi, D., Poli, G., et al. (2024) · Redox Experimental Medicine · doi:10.1530/rem-24-0013 · Cited by 2
Joyce, O., McHugh, C., Mockler, D., Wilson, F., & Kelly, Á. M. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1430382 · Cited by 3
“This result builds on the literature reporting a link between cholesterol and the development of neurodegenerative disorders associated with cognitive decline (Peters et al., 2020; Anstey et al., 2014; Anstey et al., 2017).”
Kučera, M., Šeblová, D., Bosmans, J. E., Broulíková, H. M., & Kearns, P. B. (2025) · European Journal of Public Health · doi:10.1093/eurpub/ckaf112 · Cited by 2
“Same mechanisms may underlie the nonsignificant association observed between dementia incidence and high cholesterol [39].”
Chiu, P., Chou, H., Lin, C., Li, H., Chen, T., Chen, H., & Chang, H.-T. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01910-8 · Cited by 5
Wang, X., Tian, S., Xiao, H., Chen, C., Ning, F., & Lin, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-30756-1 · Cited by 2
“A recent meta-analysis reported no significant association between HDL-C and AD risk 33 .”
Musich, M. L., Shenker, J. I., & Beversdorf, D. Q. (2026) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad3010004 · Cited by 2
do Nascimento, N. B., Farias, H. R., Schons, T., Padilha, A. P. Z., da Costa, M. S., Peres, A. M., Santos¹, L. F. D. S., Dantas, R. M., Ramos, J. M. O., Rodrigues, M. S., et al. (2026) · Neurochemical Research · doi:10.1007/s11064-025-04658-7 · Cited by 2
Začiragić, A., Valjevac, A., Dervišević, A., Fajkić, A., Spahic, S., Jadrić, R., Hasanbegović, I., & Lepara, O. (2022) · Medical Archives · doi:10.5455/medarh.2022.76.267-272 · Cited by 3
Ge, S., Kitamura, T., Zha, L., Komatsu, M., Komukai, S., Murata, F., Maeda, M., Gon, Y., Kimura, Y., Kiyohara, K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240113 · Cited by 3
“Hypercholesterolemia,aknownriskfactorfor cardiovascularandcerebrovasculardiseases,isasso-ciatedwithincreasedriskofAlzheimer’sdisease (AD)andvasculardementia[3,4].”
Dyslipidemia and cerebral atrophy among health check-up individuals: A cross-sectional study
He, X., Xiao, J., Wang, Y., Reid, C. M., Xu, D., & Hong, H. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200394 · Cited by 2
“Recent studies have shown that high midlife TC may be a risk factor for late-life dementia [4,5].”
Ng, T. K. S., Beck, T. L., Liu, X., Desai, P., Holland, T. M., Dhana, K., Krueger, K. R., Wilson, R. S., Evans, D. A., & Rajan, K. B. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.105825 · Cited by 3
Hua, J., Dong, J., Chen, Y., Li, H., & Chen, Q. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040211 · Cited by 3
Peloso, G. M., van der Lee, S. J., International Genomics of Alzheimer's Project (IGAP), Sims, R., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdóttir, J., Kunkle, B. W., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.08.008 · Cited by 3
“When evidence was combined from multiple published studies, late-life HDL-C was not associated with all-cause dementia or AD [6].”
ResultNikulina, K. V., Vorobieva, O. V., & Fateeva, V. V. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-4-25-32 · Cited by 2
Arafa, A., Kawachi, H., Kato, Y., Nosaka, S., Teramoto, M., Khairan, P., Gao, Q., Matsumoto, C., & Kokubo, Y. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123244 · Cited by 2
Nasaruddin, N. H., Ganapathy, S. S., & Tham, S. W. (2024) · Australian Journal on Ageing · doi:10.1111/ajag.13392 · Cited by 3
“46 The primary management approach for hypercholesterolemia typically encompasses a combination of lifestyle modifications and pharmacotherapy.”
Darabi, S., Gorgich, E. A. C., Rustamzadeh, A., Mohebi, N., & Mozhdehipanah, H. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.04.014 · Cited by 3
“A meta-analysis of 17 studies involving over 23,000 patients shows midlife hypercholesterolemia significantly increases the risk of developing Alzheimer ’ s disease later in life (Anstey et al., 2017).”
Hu, N., Yan, Y., Wei, S., Lv, H., Dang, L., Gao, L., Wang, J., Guo, X., Wang, J., Qu, Q., et al. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.106959 · Cited by 3
Cardiometabolic disorders and mild cognitive impairment in White and Black Americans
Kavcic, V., Turaani, M., Pal, S., Reader, J. M., & Giordani, B. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70642 · Cited by 1
Life-Course Burden of Blood Pressure Is Associated With Midlife Cognitive Function
Chen, W., Li, C., Zhang, R., Huang, Z., Li, S., Anda‐Duran, I. D., Carmichael, O. T., Ma, H., Wang, X., Kelly, T. N., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.24659 · Cited by 2
Late-onset epilepsy as a prodromal symptom
Dupont, S. (2025) · Revue Neurologique · doi:10.1016/j.neurol.2025.07.007 · Cited by 1
Ren, X., Jiang, M., Li, Y., Han, W., & Zheng, X. (2025) · Nutritional Neuroscience · doi:10.1080/1028415x.2025.2592057 · Cited by 1
“One study showed a correlation between LDL-C levels and dementia risk [35], while many studies reported no significant correlation with dementia risk [44].”
Sternberg, Z., Podolsky, R., Yu, J., Hua, S., Halvorsen, S. W., & Schaller, B. J. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100555 · Cited by 1
“A meta-analysis of 17 studies reports a relationship between total cholesterol in midlife and higher risk of AD [17].”
Hypertension acts together with Aβ pathology in late-life to promote memory loss
Ros, L. U. D., Ferrari‐Souza, J. P., Bastiani, M. A. D., Hauschild, L. A., Bellaver, B., Ferreira, P. C. L., Leffa, D. T., Povala, G., Lussier, F. Z., Chamoun, M., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100579 · Cited by 1
“Vascular risk factors (VRFs) are well-established contributors for developing dementia, and, more specifically, Alzheimer's disease (AD) [1 – 7].”
Yin, W., Peng, L., Jing-hong, Z., Huang, X., & Yin, W. (2026) · Comprehensive physiology · doi:10.1002/cph4.70146 · Cited by 1
Cardiovascular factors in dementia
Bidzan, L. (2022) · Psychiatria Polska · doi:10.12740/pp/150052 · Cited by 2
“…population sample in Denmark, which took into account not just lipid profiles but also levels of physical activity, age and the presence of other psychopathological symptoms (mainly depressive symptoms), did not report an association between higher cholesterol levels and risk of dementia [45].”
Venugopal, A., Iyer, M., Narayanasamy, A., Ravimanickam, T., Gopalakrishnan, A. V., Yadav, M., Kumar, N. S., & Vellingiri, B. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03820-y · Cited by 1
“Several studies discovered that high total cholesterol concentrations were linked to a higher risk of AD [31, 32].”
Andrén, E. A., Safi, D., Wallin, A., & Svensson, J. (2024) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2024.100229 · Cited by 3
“In contrast, in a review and meta-analysis, there were no associations between late life measurements of HDL and the risk of VaD as classified using NINDS-AIREN and other criteria [10,15].”
BackgroundMethodResultInfluentialWei, J., Lohman, M. C., Brown, M. J., Hardin, J. W., Yang, C., Merchant, A. T., & Friedman, D. B. (2024) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887241267315 · Cited by 3
Förstl, H., & Förstl, S. (2021) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-62426-5_58 · Cited by 1
Influência de indicadores biológicos e psicológicos do estresse no declínio subjetivo da memória
Matos, T. M. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.7.2018.tde-05112018-134805 · Cited by 5
Saleem, M. (2017) · TSpace (University of Toronto)
Vieira, M. C. U., Dias, D. F., Bortoletto, M. S. S., Silva, A. M. R., & Cabrera, M. A. S. (2019) · International Journal of Aging Research · doi:10.28933/ijoar-2019-06-2105
Close Relationship of Alzheimer's Disease (AD) and Glucose Dysregulation
Bando, H. (2019) · International Archives of Endocrinology Clinical Research · doi:10.23937/2572-407x.1510016
“Meta-analyses were conducted including 17 studies, 23,338 participants for 20 years [17].”
BackgroundMethodInfluentialAssociations of Serum Lipids with Risk of Cognitive Impairment in Chinese CentenariansPreprint
Chen, Y., Huang, Y., Ning, C., Zhu, Q. L., Yao, Y., & Zhao, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-274807/v1
Wang, Q., Zang, F., He, C., Zhang, Z., & Xie, C. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3904355
Complementary Medications (Statins, Nicergoline, Naftidrofuryl) in Dementia
Yaman, A., & Yaman, H. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_422-1
Effects of Apolipoprotein E Gene and Sex On Serum Lipid Profiles in Alzheimer's DiseasePreprint
Fu, J., Huang, Y. Y., Bao, T., Ou, R., Wei, Q., Chen, Y., Yang, J., Chen, X., & Shang, H. (2021) · Research Square · doi:10.21203/rs.3.rs-1140484/v1
INCREASING THE ACCURACY OF THE DIAGNOSIS OF MENTAL DISORDERS BASED ON HETEROGENEOUS DISTRIBUTED DATA
Богданов, А. В., Degtyarev, A., Zalutskaya, N. M., Gomzyakova, N. A., Belavin, S., & Khokhryakova, A. (2021) · 9th International Conference "Distributed Computing and Grid Technologies in Science and Education" · doi:10.54546/mlit.2021.55.82.001
“In particular, neuropsychological examination [2], magnetic resonance imaging (MRI) [3], electroencephalography (EEG) [4], blood tests [5], genotyping [6] are used in the field of brain pathologies research.”
Background
Metadata
- Authors
- Anstey, K. J., Ashby-Mitchell, K., & Peters, R.
- Affiliations
- Australian National University (AU)
- Corresponding author
- Anstey, Kaarin J.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-11-29
- Volume
- 56
- Issue
- 1
- Pages
- 215-228
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5240556
- OpenAlex
- W2558803774
- Semantic Scholar
- 0c1251803f118cf5e382bfc6624ab0fbd3c53d8f
- Cited by
- 360
- References
- 61
- Citations by year
- 2026: 18 · 2025: 42 · 2024: 52 · 2023: 43 · 2022: 52 · 2021: 51 · 2020: 43 · 2019: 34 · 2018: 18 · 2017: 7
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- ANU Open Research (Australian National University) (submittedVersion, cc-by-nc)
- Funders
- National Institute for Health and Care Research (PDF-2012-05-197)
- National Health and Medical Research Council (1002560)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- serum cholesterol
- MeSH terms
- Alzheimer Disease, Cholesterol, Dementia, Humans, Risk Factors, Cohort Studies, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
